PMCPA Case
| Case number | AUTH/2981/9/17 |
| Complainant | Member of the public |
| Company | ViiV Healthcare |
| Product | Triumeq (dolutegravir/abacavir/lamivudine) |
| Issue | Promotional material visible on an iPad on a train (public setting) |
| Applicable Code year | 2016 |
| Clauses considered | 2, 9.1, 15.2, 26.1 |
| Panel decision | No breach of the Code |
| Key reasoning | No representative as defined by the Code was involved; material not directed at the public; difference between proactive public promotion vs someone reading over a shoulder |
| Complaint received | 26 September 2017 |
| Case completed | 23 November 2017 |
| Appeal | No appeal |
Download the full case report (PDF)
Reviewed by Dr Anzal Qurbain (FFPM) — ABPI Final Signatory
Got a question about this case?
Ask one of our 13 specialist ABPI advisors — instant answers, 24/7.
⭐ Business Intelligence Access
See the full compliance picture for every pharma company
291 Company Intelligence Reports — breach patterns, appeal history, industry ranking, PDF export.
One real case. One key lesson. Every week — free.